|
ONC201 Clinical Trials
3 actively recruiting trials across 2 locations
Also known as: Antagonist of dopamine receptor D2 (DRD2) and caseinolytic protease proteolytic subunit (ClpP), TIC10
Pipeline
Phase 1: 1Phase 2: 1Phase 3: 1
Top Sponsors
- University of California, San Francisco1
- UNC Lineberger Comprehensive Cancer Center1
- Gustave Roussy, Cancer Campus, Grand Paris1
Indications
- Cancer3
- Diffuse Midline Glioma, H3 K27M-Mutant2
- Diffuse Intrinsic Pontine Glioma2
- Clear Cell Endometrial Carcinoma1
- Serous Adenocarcinoma of Endometrium (Diagnosis)1
Other1 trial
Birmingham, Alabama1 trial
Combination Therapy for the Treatment of Diffuse Midline Gliomas
University of Alabama at Birmingham
Phase 2
Chapel Hill, North Carolina1 trial
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Lineberger Comprehensive Cancer Center
Phase 1
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.